# Trends, Seasonality, and the Impact of COVID-19 on Clinical Staphylococcus aureus and MRSA Isolates in Western Mexico (2016–2025): A Time-Series Analysis at a University Referral Hospital

**Authors:** Jaime Briseno-Ramírez, Pedro Martínez-Ayala, Adolfo Gómez-Quiroz, Brenda Berenice Avila-Cardenas, Brian Rafael Rubio-Mora, Roberto Miguel Damian-Negrete, Ana María López-Yáñez, Leonardo García-Miranda, Carlos Roberto Álvarez-Alba, Judith Carolina De Arcos-Jiménez

PMC · DOI: 10.3390/antibiotics15030242 · Antibiotics · 2026-02-25

## TL;DR

This study shows a significant drop in MRSA prevalence and incidence in a Mexican hospital during and after the COVID-19 pandemic.

## Contribution

The study provides longitudinal data on MRSA trends in a Latin American hospital during the pandemic, revealing a sustained decline post-peak.

## Key findings

- MRSA prevalence dropped from 28.1% to 14.0% after the pandemic peak.
- MRSA incidence density decreased by 50%, while overall S. aureus rates remained stable.
- MRSA showed minimal seasonality compared to S. aureus, which peaked in May–July.

## Abstract

Background/Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) remains a major cause of both community-onset and hospital-acquired infections, yet longitudinal data from Latin American hospitals spanning the COVID-19 pandemic are scarce. We characterized temporal trends, seasonality, and the impact of the COVID-19 pandemic on MRSA prevalence and incidence density among clinical S. aureus isolates at a tertiary-care hospital in western Mexico over 9.5 years. Methods: We analyzed 6625 non-duplicate clinical S. aureus isolates (6609 with valid resistance data) from June 2016 to December 2025. Temporal trends were assessed using Mann–Kendall tests, Theil–Sen estimation, and binomial generalized linear models. Seasonality was evaluated through STL decomposition, generalized additive models, and Fourier analysis. An interrupted time series (ITS) model with GLS-AR(1) and Newey–West corrections compared three COVID-19 phases: pre-pandemic (2016–2020), high viral circulation (2020–2022), and post-peak stabilization (2022–2025). Exposure-adjusted incidence densities (per 1000 patient-days) were analyzed in parallel. Results: MRSA prevalence declined from 28.1% pre-pandemic to 14.0% post-peak (Mann–Kendall z = −9.03, p < 0.001; OR = 0.85 per year, 95% CI: 0.829–0.871). MRSA incidence density decreased by 50%, from 1.27 to 0.63 per 1000 patient-days, while aggregate S. aureus incidence density remained stable (z = −0.17, p = 0.868). The ITS joint Wald test confirmed a significant cumulative shift in MRSA trajectory post-pandemic (p = 0.019 counts; p = 0.012 incidence density), with a significant post-peak level drop (p = 0.008). S. aureus exhibited moderate seasonality peaking in May–July (GAM edf = 7.26, p < 0.001), whereas MRSA showed only marginal seasonal variation. Conclusions: MRSA declined markedly across the study period, with the steepest reduction following the Omicron peak. The decline persisted after adjustment for pandemic-related fluctuations in hospital volume, supporting periodic reassessment of empiric anti-MRSA prescribing policies in similar settings.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)
- **Species:** Staphylococcus aureus (taxon 1280)

## Full-text entities

- **Diseases:** abscess infections (MESH:D000038), pneumonia (MESH:D011014), bacteremia (MESH:D016470), AMR infections (MESH:D007239), injury to (MESH:D014947), abscess-site infections (MESH:D013530), AMR (MESH:D060467), ventilator (MESH:D053717), associated (MESH:D018886), Bloodstream infections (MESH:D018805), Meningitis (MESH:D008580), pressure ulcer infections (MESH:D003668), COVID-19 (MESH:D000086382), MRSA (MESH:D013203), HAI (MESH:D003428), Infectious Diseases (MESH:D003141)
- **Chemicals:** lubridate (-), Methicillin (MESH:D008712), oxacillin (MESH:D010068), Cefoxitin (MESH:D002440), vancomycin (MESH:D014640), linezolid (MESH:D000069349)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** ATCC 25923 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024594/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024594/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024594/full.md

---
Source: https://tomesphere.com/paper/PMC13024594